IMAGE: This is Padmanee Sharma, M.D., Ph.D. view more
Credit: MD Anderson Cancer Center
HOUSTON – Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson Cancer Center, has been recognized for her innovative work understanding factors that enhance and hinder cancer immunotherapy. Sharma will receive the William B. Coley Award for Distinguished Research in Tumor Immunology, awarded annually by the Cancer Research Institute (CRI), at an annual meeting co-sponsored by CRI in New York Sept. 30 to Oct. 3.
“CRI has played an inspiring and central role in advancing cancer immunotherapy, so I’m honored and excited to earn this recognition,” says Sharma. “Immune checkpoint therapy has improved survival and provided durable clinical responses for thousands of advanced-stage patients with different cancer types, yet there’s more for us to learn in order to increase the number of patients who benefit from this novel treatment.”
Immune checkpoint drugs enable T cells, the soldiers of the immune system, to work better by blocking inhibitory proteins on T cells that normally act to limit T cell responses.
“Science-driven efforts led by Dr. Sharma and recognized by CRI are crucial for identifying mechanisms of response
Article originally posted at